We are on our way to become one of the global leaders in TPD technology. Therefore, we cannot miss the upcoming Congress #BIO2023 in Boston to present our research progress and development goals for the upcoming years. We look forward to seeing you!

20 employees of Captor Therapeutics took part in the 11th edition of Fundacja Everest - the charity relay race, the main goal of which is to help and raise funds for the treatment and rehabilitation of the beneficiaries of the Everest Foundation.

We have just recently published our Full Year Report for 2022!
We would like to thank all our stakeholders for their support in achieving yet so many milestones in our development.
captortherapeutics.com/news/77/captor…

Captor Therapeutics joins PACS2 Research Foundation to help identify treatments for ultrarare PACS2 disease, the only institution in the world, working for those impacted by this syndrome.

#PACS2ResearchFoundation

Conventional anti-cancer therapies often fall short. At Captor Therapeutics, we're changing the game with targeted protein degradation therapy. Earmark cancer-causing proteins for elimination. A new hope for cancer patients.
#cancerresearch #targetedproteindegradation

Na dobry początek tygodnia zapraszamy do przeczytania wywiadu z Michałem Walczakiem i Radosławem Krawczykiem, w którym opowiadają o najnowszych spostrzeżeniach na temat Spółki, a także przedstawią aktualną sytuację na rynku TPD.
strefainwestorow.pl/artykuly/wywia…

Looking forward to meeting investors, partners, and fellow TPD-innovators this week in San Francisco during #JPM23 . Schedule a meeting to connect: [email protected]

#JPM2023 #JPMWeek

All the best for the New Year! The last 12 months for our company were remarkable. We achieved several milestones in developing our lead projects which are now approaching the clinic and signed a major collaboration with Ono Pharmaceutical.
We definitely won’t stop in 2023!

Thanks to the commitment of our employees we managed to prepare a grand set of gifts including toys, board games, art supplies as well as self-care products. We hope that it will help to brighten up the festive season of small patients!

Captor’s festive bonding! Before a few deserved days off with our families & friends, our Team got together to support a local animal shelter. Secret Santa also paid us a visit with some little gifts.

Captor Therapeutics Chief Executive Officer, Tom Shepherd, and Chief Scientific Officer, Michal Walczak, will be in San Francisco during the J.P. Morgan 41st Annual Healthcare Conference to meet with investors and potential strategic partners.
#JPMorganHealthcare

Piotr Kowalczyk – Principal Scientist in Drug Development & Jola Skalska – Principal Scientist, took part in ESMO - Eur. Oncology in Singapore, to talk about our CT-03 project, aimed at tackling liquid & solid tumors. We expect to start clinical trials in 2023/24.

Our corporate report for Q3 2022 is now published.

Captor`s lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical that could generate up to €197 million.

Check full report for Q3 here:
captortherapeutics.com/investors-rela…

Captor Therapeutics announces global collaboration with Ono Pharmaceutical to leverage TPD discovery platform in a new and unprecedented way of targeting neurodegenerative disease, an area of widespread and critical unmet medical need
captortherapeutics.com/news/66/ono-ph…

Meet our CEO, Tom Shepherd, at Jefferies London Healthcare Conference!

What are Captor`s main strengths? Obviously - the innovative technology and The Team! We are proud to have so many talented scientists in our company. One of them Krzysztofa Odrzywol, PhD, Principal Scientist, was recently interviewed by ForbesWomen.

forbes.pl/forbeswomen/br…

To all those interested in Captor`s work, TDP technology and just simply wanting to know more about our company`s everyday tasks – you just have to watch the latest interview of our Chief Scientific Officer Michal J. Walczak!

youtube.com/watch?v=AgE7oE…

We are pleased to announce that Captor Therapeutics CEO Dr. Tom Shepherd will take part in a panel discussion entitled “Bullseye – Targeted Oncology – In with the New” at next month’s Wedbush PacGrow Healthcare Conference – click here for more information: captortherapeutics.com/news/60/captor…

Join us for Captor Therapeutics SA's R&D Day on Wednesday 18 May at 10:00 am EDT (04:00 pm CEST). We’ll be discussing our TPD discovery platform and the potential of our CT-01 program to redefine the hepatocellular carcinoma treatment paradigm. Register Here: lifesci.events/CTX

Join us live for Captor Therapeutics’ R&D Day on Wednesday 18 May at 10:00 am EDT (04:00 pm CEST).
Click here: lnkd.in/eMM-QDiV to register and here: [email protected] to submit a question and join the discussion.